Table of Contents
The mechanism of action of dapagliflozin is a key aspect of its role in managing type 2 diabetes. It targets a specific process in the kidneys that affects blood glucose levels.
Overview of Kidney Glucose Reabsorption
The kidneys play a crucial role in maintaining blood glucose homeostasis. They filter blood through the glomeruli, and glucose is freely filtered into the renal tubules. Under normal conditions, most of this glucose is reabsorbed back into the bloodstream.
Role of SGLT2 in Glucose Reabsorption
The sodium-glucose co-transporter 2 (SGLT2) is primarily responsible for reabsorbing approximately 90% of the filtered glucose in the proximal tubules of the kidney. It co-transports sodium ions and glucose from the tubular lumen into the renal epithelial cells.
Mechanism of Dapagliflozin
Dapagliflozin is a selective inhibitor of SGLT2. By binding to this transporter, it prevents the reabsorption of glucose in the proximal tubules. As a result, more glucose remains in the tubular lumen and is excreted in the urine.
Impact on Blood Glucose Levels
The increased urinary glucose excretion lowers blood glucose levels, which is beneficial for patients with type 2 diabetes. This mechanism reduces hyperglycemia without relying on insulin secretion or sensitivity.
Additional Effects of Dapagliflozin
Besides lowering blood glucose, dapagliflozin also contributes to weight loss and blood pressure reduction. These effects result from the osmotic diuresis caused by increased glucose and sodium excretion.
Summary
Dapagliflozin acts by selectively inhibiting SGLT2 in the kidney, decreasing glucose reabsorption, and promoting its excretion. This mechanism provides an insulin-independent approach to managing hyperglycemia in type 2 diabetes patients.